PharmaCyte Biotech Inc (OTCMKTS:PMCB) Climbing The Ladder

[[tagnumber 0]][[tagnumber 1]]After sliding throughout most of this year we finally saw PharmaCyte Biotech Inc (OTCMKTS:PMCB) begin to climb the charts in the end of last month. After a few hiccups it managed to gain some decent altitude and pass above the 10 cent per share mark.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The reason for the upward run is the wave of positive press releases, as well as some promotional activity. The company itself looks like your regular OTC marketplace biotech. The market value of $86 million is backed up by these numbers that were contained in [[tagnumber 6]]PMCB’s[[tagnumber 7]] report for the quarter ended July 31, 2015.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 11]] [[tagnumber 12]]cash: $2.91 million[[tagnumber 13]] [[tagnumber 12]]current assets: $3.01 million[[tagnumber 13]] [[tagnumber 12]]current liabilities: $1.18 million[[tagnumber 13]] [[tagnumber 12]]revenues: $0[[tagnumber 13]] [[tagnumber 12]]loss from operations: $1 million[[tagnumber 13]] [[tagnumber 22]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Meanwhile, the company is still conducting trials for its Cell–in–a–Box® encapsulation technology. A big step that they made was to receive an Orphan Drug Status from the FDA, something they are looking to secure with the European Medicines Agency (EMA) at this time.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]After more positive PR we saw [[tagnumber 6]]PMCB[[tagnumber 7]] climb 11.88% in yesterday’s session and finish at $0.1158. A total of 3.47 million shares changed their owners and generated $391 thousand in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]][[tagnumber 6]]PMCB[[tagnumber 7]] is moving in the green today, but you should still be careful, as the stock is still freshly pumped and volatile.[[tagnumber 2]]